According to Reuters, shares in Amazon (AMZN) dropped on concerns about margins in it latest earnings. Reuters writes that RIM (RIMM) will start to market its Blackberry in China. Reuters reports that…
Two more studies show that GlaxoSmithKline (GSK) blockbuster diabetes drug Avandia has significant health risks. According to The Wall Street Journal "the Food and Drug Administration is considering whether Avandia’s use should…
Douglas A. McIntyre Markets in Europe were higher at 6.05 AM New York time. The FTSE rose 1.1% to 6,264. Barclays (BCS) rose 1.5% to 642.5. GlaxoSmithKline (GSK) rose 1.4% to 1305. The DAXX rose…
Markets in Europe were higher at 5,40 AM New York time. The FTSE rose 1% to 6,126. BHP Billiton (BHP) was up 4.4% to 1278. GlaxoSmithKline (GSK) was up 1% to 1284.…
Markets in Europe were off modestly at 5.50 AM New York time. The FTSE fell .2% to 6,211. Barclays (BCS) was up 2.4% to 594.5. BHP Billiton (BHP) was off 1.4 to…
Pozen (POZN) got the bad news that the FDA has "delayed approval of an experimental two-in-one migraine drug from GlaxoSmithKline (GSK)", according to Reuters. The drug, Trexima combines Glaxo’s popular migraine drug…
Douglas A. McIntyre The U.S. Centers for Medicare & Medicaid Services issued its final ruling governing use of a class of anemia drugs including Amgen’s (AMGN) Aranesp .The CMOS guided doctors to restrict the use…
Markets in Europe were higher at 6.50 AM New York time. The FTSE rose .7% to 6,295. BP (BP) was down 1.4% to 565.5. BT (BT) was up 1.9% to 315.75. GSK…
Markets in Europe were up sharply at 6 AM New York time. The FTSE rose 1.6% to 6,306. Barclays (BCS) was up 2.1% to 695. BHP Billiton (BHP) was up 2.6% to…
GlaxoSmithKline (GSK) wants everyone, including the FDA, to know that its diabetes drug Avadia is "safe and effective when used appropriately." Almost everyone else thinks that the drug increases risk of heart…
Douglas A. McIntyre Amgen (AMGN) actually rallied a bit after hours yesterday. But, revenue growth was hard to come by. Amgen reported net income of $1.02 billion, or 90 cents per share, for the quarter…
Sales of GlaxoSmithKline’s (GSK) Avandia products for diabetes dropped 22% because of health concerns about the drug. And the company’s overall reveue missed analyst forecasts. But, the company announced that it would…
Douglas A. McIntyre Imagine that if an aspirin did not get rid of you headache. And, the company that made the pain killer gave you your money back. A new proposal by Johnson & Johnson…
As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but…
GlaxoSmithKline (GSK-NYSE) has been under significant pressure of late because of the New England Journal of Medicine showing greatly increased risks of a heart attack for diabetes patients that have taken AVANDIA. …
Douglas A. McIntyre 